by kati.sallinen@desentum.fi | Apr 2, 2025 | News
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch...
by kati.sallinen@desentum.fi | Jun 10, 2024 | News
Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department of Chemistry at the...